BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nventa Biopharmaceuticals Corporation (NVN.TO) Granted European Patent Covering Heat Shock Protein Fusion To Treat Influenza


6/7/2006 11:06:20 AM

SAN DIEGO, CA, June 7 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX: NVN - News) announced that the European Patent Office has granted Patent Number EP 941,315 to Nventa. The patent covers compositions of fusion proteins comprised of an influenza antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins.

"Our proprietary CoVal(TM) fusion proteins represent an exciting approach to developing a therapeutic treatment for a broad class of current and emerging strains of the influenza virus," said Gregory M. McKee, President and Chief Executive Officer at Nventa. "We have generated promising preclinical data with our Hsp-influenza fusion protein candidate, which utilizes the highly conserved internal protein, NP, or nucleoprotein, to elicit a targeted cytotoxic T lymphocyte response against several flu strains."

While several companies are working on prophylactic vaccines, Nventa is one of the few companies working on a treatment, or therapeutic vaccine, for influenza. There is worldwide concern today regarding a pandemic outbreak of influenza that could affect large populations around the world.

Nventa has already generated prototypes of Hsp fusion proteins with influenza antigens. These prototypes have shown activity in preclinical models that suggest their potential utility as a treatment for common and avian flu. In mice, these fusions have been shown to elicit T cell-mediated immune responses that recognize appropriate influenza antigens. This type of immune response has also been shown to produce the cytokine interferon gamma, which is known to have anti-viral activity.

About Influenza:

----------------

Every year, 10 to 20 percent of Americans get sick with the flu (influenza). In the United States, approximately 25 percent of the population has flu-associated illness annually, leading to an average of 20,000 to 40,000 deaths per year. The U.S. Centers for Disease Control and Prevention (CDC) estimates that 35 to 50 million Americans come down with the flu during each flu season, which typically lasts from November to March.

About Nventa Corporation:

------------------------- Nventa is developing innovative therapeutics for the treatment of viral infections, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit the website located at www.nventacorp.com.

Contact: --------

Donna Slade Director, Investor Relations 6055 Lusk Boulevard San Diego, CA USA 92121 Dir: 858.202.4945 dslade@nventacorp.com

Source: Stressgen Biotechnologies Corp.



Read at BioSpace.com

   
Influenza

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES